Pear Therapeutics To Release PEAR-004 To Help Individuals With Schizophrenia During COVID-19 Crisis

Pear Therapeutics, Inc., a leader in prescription digital therapeutics (PDTs), announced that it is launching a limited distribution program for its product candidate, Pear-004, for people living with schizophrenia. Based on the U.S. Food and Drug Administration's (FDA) Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 Public Health Emergency, Pear plans to provide consumers with access to Pear-004 through collaborations with select health care provider organizations and academic centers. Unlike Pear’s FDA-authorized products, reSET®, reSET-O®, and Somryst™, Pear-004 has not received market authorization from FDA . . .